Robert Zivadinov

List of Publications by Year
in descending order

521 papers	21,507 citations	9786 73 h-index	21540 114 g-index
527 all docs	527 docs citations	527 times ranked	15613 citing authors

#	Article	IF	Citations
1	Staging and stratifying cognitive dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 463-471.	3.0	17
2	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Multiple Sclerosis Journal, 2022, 28, 1101-1111.	3.0	23
3	Functional network dynamics and decreased conscientiousness in multiple sclerosis. Journal of Neurology, 2022, 269, 2696-2706.	3.6	9
4	MRIâ€based thalamic volumetry in multiple sclerosis using FSLâ€FIRST: Systematic assessment of common error modes. Journal of Neuroimaging, 2022, 32, 245-252.	2.0	1
5	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders, 2022, 57, 103406.	2.0	9
6	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis. Brain Imaging and Behavior, 2022, 16, 1252-1259.	2.1	3
7	Editorial of Special Issue â€œMultiple Sclerosis: From Diagnostic Biomarkers to Imaging and Clinical Predictorsâ€. Diagnostics, 2022, 12, 482.	2.6	0
8	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. Journal of Neuroimaging, 2022, 32, 910-919.	2.0	2
9	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis. European Radiology, 2022, , 1.	4.5	1
10	Time course of lesion-induced atrophy in multiple sclerosis. Journal of Neurology, 2022, 269, 4478-4487.	3.6	3
11	Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease. Movement Disorders, 2022, 37, 490-501.	3.9	10
12	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients. European Journal of Neurology, 2022, , .	3.3	1
13	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103906.	2.0	1
14	Neurofilament levels are associated with bloodâ€“brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	3.0	55
15	Recovery of cognitive function after relapse in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 71-78.	3.0	38
16	Diagnosis of depression in multiple sclerosis is predicted by frontalâ€“parietal white matter tract disruption. Journal of Neurology, 2021, 268, 169-177.	3.6	10
17	Conscientiousness and deterioration in employment status in multiple sclerosis over 3â€‰years. Multiple Sclerosis Journal, 2021, 27, 1125-1135.	3.0	11
18	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Crossâ€Sectional Structural <scp>MRI</scp> Study. Journal of Magnetic Resonance Imaging, 2021, 53, 731-739.	3.4	19

#	Article	IF	Citations
19	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102653.	2.0	13
20	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Multiple Sclerosis Journal, 2021, 27, 1077-1087.	3.0	18
21	Interpretation of Brain Volume Increase in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 401-407.	2.0	6
22	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	2.7	5
23	Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199239.	1.0	5
24	Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. Experimental Neurology, 2021, 335, 113488.	4.1	8
25	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. NeuroImage: Clinical, 2021, 29, 102554.	2.7	3
26	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. NeuroImage: Clinical, 2021, 31, 102705.	2.7	3
27	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. Journal of Neurology, 2021, 268, 2578-2588.	3.6	18
28	Measuring Aqueduct of Sylvius Cerebrospinal Fluid Flow in Multiple Sclerosis Using Different Software. Diagnostics, 2021, 11, 325.	2.6	1
29	Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Review of Neurotherapeutics, 2021, 21, 353-364.	2.8	11
30	Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 515-527.	2.9	53
31	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
32	A randomized evaluation of the TriGuardâ„¢ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal, 2021, 42, 2670-2679.	2.2	39
33	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. Journal of Neurology, 2021, 268, 4796-4808.	3.6	3
34	The cholesterol autoxidation products, 7-ketocholesterol and 7Î²-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102864.	2.0	3
35	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. Journal of Neuroimaging, 2021, 31, 995-1002.	2.0	3
36	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. Journal of the Neurological Sciences, 2021, 427, 117552.	0.6	10

#	Article	IF	Citations
37	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. Neurodegenerative Disease Management, 2021, 11, 329-340.	2.2	4
38	DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis. NeuroImage: Clinical, 2021, 30, 102652.	2.7	10
39	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron <scp>MRI</scp>. Human Brain Mapping, 2021, 42, 1463-1474.	3.6	27
40	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	3.0	9
41	Editorial: Update on Vascular Contributions to Age-Related Neurodegenerative Diseases and Cognitive Impairment - Research of ISNVD 2020 Meeting. Frontiers in Neurology, 2021, 12, 797486.	2.4	1
42	Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110615.	1.0	2
43	CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110603.	1.0	8
44	Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis Journal, 2020, 26, 99-108.	3.0	27
45	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 245-252.	3.0	12
46	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Multiple Sclerosis Journal, 2020, 26, 201-209.	3.0	24
47	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Multiple Sclerosis Journal, 2020, 26, 322-332.	3.0	28
48	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1433-1436.	3.0	8
49	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis Journal, 2020, 26, 1670-1681.	3.0	61
50	Tagged cine magnetic resonance imaging to quantify regional mechanical changes after acute myocardial infarction. Magnetic Resonance Imaging, 2020, 66, 208-218.	1.8	10
51	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of followâ€up. European Journal of Neurology, 2020, 27, 188.	3.3	26
52	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. European Journal of Neurology, 2020, 27, 235-243.	3.3	9
53	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. Journal of Vascular Research, 2020, 57, 16-23.	1.4	7
54	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. Journal of Neurology, 2020, 267, 802-811.	3.6	11

#	Article	IF	Citations
55	Late onset multiple sclerosis is associated with more severe ventricle expansion. Multiple Sclerosis and Related Disorders, 2020, 46, 102588.	2.0	13
56	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	1.5	8
57	Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients. Diagnostics, 2020, 10, 942.	2.6	3
58	Use of patient-reported data in determining factors contributing to internal jugular vein stenosis outcomes. Annals of Translational Medicine, 2020, 8, 421-421.	1.7	2
59	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097075.	3.5	7
60	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 553616.	2.4	4
61	Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety, 2020, 19, 1121-1142.	2.4	16
62	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. Frontiers in Neurology, 2020, 11, 700.	2.4	12
63	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102389.	2.0	15
64	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1577-1583.	2.4	4
65	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics, 2020, 10, 685.	2.6	4
66	Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIOâ€Enhanced Ultrahighâ€Field Imaging. Journal of Neuroimaging, 2020, 30, 769-778.	2.0	8
67	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117120.	0.6	5
68	Sexâ€Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 342-350.	2.0	12
69	Functional Connectivity and Structural Disruption in the Defaultâ€Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 523-530.	2.0	21
70	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. Multiple Sclerosis and Related Disorders, 2020, 42, 102131.	2.0	3
71	Cervical Spinal Cord Lesions and Atrophy versus Brain Measures in Explaining Physical Disability in Multiple Sclerosis. Radiology, 2020, 296, 616-618.	7.3	3
72	Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090248.	1.0	2

#	Article	IF	Citations
73	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinsonâ€™s disease, mild cognitive impairment, Alzheimerâ€™s disease, and elderly healthy controls. Neurobiology of Aging, 2020, 90, 84-92.	3.1	14
74	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines, 2020, 8, 50.	4.4	37
75	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 821-834.	2.8	17
76	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
77	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 294-300.	0.9	3
78	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. Fluids and Barriers of the CNS, 2020, 17, 9.	5.0	7
79	Serum neurofilament light chain and optical coherence tomography measures in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
80	Magnetic Resonance Imaging and Analysis in Multiple Sclerosis. Current Clinical Neurology, 2020, , 109-136.	0.2	3
81	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5â€year longitudinal study. European Journal of Neurology, 2019, 26, 87.	3.3	72
82	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	2.5	6
83	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. Multiple Sclerosis Journal, 2019, 25, 1243-1254.	3.0	33
84	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology, 2019, 93, e611-e623.	1.1	30
85	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegenerative Disease Management, 2019, 9, 149-172.	2.2	41
86	Serum neurofilament light chain levels associations with gray matter pathology: a 5â€year longitudinal study. Annals of Clinical and Translational Neurology, 2019, 6, 1757-1770.	3.7	66
87	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: AAfatigue-metabolism nexus?. Journal of Clinical Lipidology, 2019, 13, 654-663.e1.	1.5	17
88	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 615-623.	2.0	8
89	Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRIâ€“based Decoupling of Complex Relationships. Radiology, 2019, 292, 458-459.	7.3	1
90	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Human Brain Mapping, 2019, 40, 5231-5241.	3.6	37

#	Article	IF	Citations
91	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	7.3	36
92	Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders. CNS Drugs, 2019, 33, 1073-1086.	5.9	10
93	Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101388.	2.0	22
94	Characterization of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Experimental Neurology, 2019, 314, 82-90.	4.1	21
95	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Multiple Sclerosis and Related Disorders, 2019, 34, 103-111.	2.0	24
96	Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease. Movement Disorders, 2019, 34, 1006-1013.	3.9	51
97	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. Journal of Lipid Research, 2019, 60, 1190-1198.	4.2	31
98	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5â€‰years. BMC Neurology, 2019, 19, 121.	1.8	5
99	Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis. Life Sciences, 2019, 229, 116-123.	4.3	4
100	Aging and Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 527-535.	2.0	33
101	Epidemiology and treatment of multiple sclerosis in elderly populations. Nature Reviews Neurology, 2019, 15, 329-342.	10.1	185
102	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. Expert Review of Neurotherapeutics, 2019, 19, 445-458.	2.8	25
103	Cognitive Profiles of Aging in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2019, 11, 105.	3.4	43
104	A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2019, 40, 446-452.	2.4	15
105	Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. American Journal of Neuroradiology, 2019, 40, 620-625.	2.4	22
106	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. Journal of Clinical Medicine, 2019, 8, 344.	2.4	17
107	Coagulation Pathways in Neurological Diseases: Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 409.	2.4	38
108	Reinforcer pathology: Common neural substrates for delay discounting and snack purchasing in prediabetics. Brain and Cognition, 2019, 132, 80-88.	1.8	12

#	Article	IF	Citations
109	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. Journal of Comparative Effectiveness Research, 2019, 8, 305-316.	1.4	14
110	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. Journal of Neurology, 2019, 266, 866-875.	3.6	36
111	Decrease in size of secondary neck vessels and cerebral aqueduct enlargement in multiple sclerosis: a 5-year longitudinal MRI study. Veins and Lymphatics, 2019, 8, .	0.1	0
112	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. Thrombosis and Haemostasis, 2019, 119, 175-178.	3.4	6
113	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. Multiple Sclerosis and Related Disorders, 2019, 27, 298-304.	2.0	16
114	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. NeuroImage, 2019, 186, 308-320.	4.2	25
115	Plasma levels of soluble NCAM in multiple sclerosis. Journal of the Neurological Sciences, 2019, 396, 36-41.	0.6	13
116	Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 514-521.	1.9	66
117	Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. Journal of Neuroimaging, 2019, 29, 52-61.	2.0	17
118	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders, 2019, 27, 65-73.	2.0	6
119	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	3.0	32
120	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. Current Neurovascular Research, 2019, 16, 215-223.	1.1	6
121	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regeneration Research, 2019, 14, 373.	3.0	114
122	Marijuana Use by Patients with Multiple Sclerosis. International Journal of MS Care, 2019, 21, 57-62.	1.0	10
123	Establishing pathological cut-offs for lateral ventricular volume expansion rates. NeuroImage: Clinical, 2018, 18, 494-501.	2.7	26
124	The Role of Highâ€Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 328-337.	2.0	4
125	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. Journal of Alternative and Complementary Medicine, 2018, 24, 596-602.	2.1	31
126	No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. Current Medical Research and Opinion, 2018, 34, 1431-1440.	1.9	6

#	Article	IF	Citations
127	Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 384-392.	2.9	20
128	Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease. American Journal of Neuroradiology, 2018, 39, 479-484.	2.4	47
129	Effect of switching from glatiramer acetate 20â€¯mg/daily to glatiramer acetate 40â€¯mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. Journal of the Neurological Sciences, 2018, 387, 152-156.	0.6	7
130	Longitudinal personality change associated with cognitive decline in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1909-1912.	3.0	24
131	Susceptibility Weighted MRI in Rodents at 9.4 T. Methods in Molecular Biology, 2018, 1718, 205-234.	0.9	3
132	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 642-647.	2.4	38
133	Assessing â€˜No Evidence of Disease Activityâ€™ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. CNS Drugs, 2018, 32, 75-84.	5.9	31
134	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2018, 39, 289-295.	2.4	24
135	Interferon Î² for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032003.	6.2	116
136	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. European Journal of Neurology, 2018, 25, 584-e36.	3.3	11
137	Extracranial venous angioplasty is ineffective to treat MS. Nature Reviews Neurology, 2018, 14, 129-130.	10.1	8
138	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. Journal of the Neurological Sciences, 2018, 388, 175-181.	0.6	15
139	Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimerâ€™s disease. Multiple Sclerosis and Related Disorders, 2018, 22, 52-56.	2.0	17
140	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. NeuroImage: Clinical, 2018, 18, 1007-1016.	2.7	32
141	Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?. Multiple Sclerosis Journal, 2018, 24, 205-213.	3.0	16
142	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. European Heart Journal, 2018, 39, 1687-1697.	2.2	38
143	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. NeuroImage, 2018, 167, 438-452.	4.2	60
144	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 123-130.	2.4	25

#	Article	IF	Citations
145	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. NeuroImage: Clinical, 2018, 17, 530-540.	2.7	32
146	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage: Clinical, 2018, 17, 444-451.	2.7	58
147	Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis. Quantitative Imaging in Medicine and Surgery, 2018, 8, 979-983.	2.0	14
148	103â€…Exploring the influence of quantitative magnetic resonance imaging on decision-making in multiple sclerosis clinical practice. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A41.1-A41.	1.9	1
149	An Exploratory Study of Mild Cognitive Impairment of Retired Professional Contact Sport Athletes. Journal of Head Trauma Rehabilitation, 2018, 33, E16-E23.	1.7	21
150	A Preliminary Study of Early-Onset Dementia of Former Professional Football and Hockey Players. Journal of Head Trauma Rehabilitation, 2018, 33, E1-E8.	1.7	21
151	Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. Journal of Head Trauma Rehabilitation, 2018, 33, E24-E32.	1.7	25
152	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. American Journal of Neuroradiology, 2018, 39, 2237-2242.	2.4	25
153	Quantitative susceptibility mapping (QSM) with an extended physical model for MRI frequency contrast in the brain: a proofâ€ofâ€concept of quantitative susceptibility and residual (QUASAR) mapping. NMR in Biomedicine, 2018, 31, e3999.	2.8	17
154	TCT-43 First-in-human experience of a novel transradial device for embolic deflection during transcatheter aortic valve replacement. Journal of the American College of Cardiology, 2018, 72, B19.	2.8	2
155	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsingâ€“Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs, 2018, 32, 763-770.	5.9	14
156	Jugular Venous Flow Quantification Using Doppler Sonography. Ultrasound in Medicine and Biology, 2018, 44, 1762-1769.	1.5	12
157	Why Is Cognitive Impairment Present in Multiple Sclerosis? Insights from Functional MRI. Radiology, 2018, 288, 552-553.	7.3	2
158	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 490-495.	2.0	50
159	Hemostasis biomarkers in multiple sclerosis. European Journal of Neurology, 2018, 25, 1169-1176.	3.3	25
160	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. American Journal of Neuroradiology, 2018, 39, 1480-1486.	2.4	13
161	Extracranial Veins in Multiple Sclerosis: Is There a Role for Vascular Surgery?. European Journal of Vascular and Endovascular Surgery, 2018, 56, 618-621.	1.5	8
162	Reply. JACC: Cardiovascular Interventions, 2018, 11, 1420.	2.9	0

#	Article	IF	Citations
163	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology, 2018, 289, 487-496.	7.3	75
164	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2018, 25, 37-42.	2.0	11
165	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Human Brain Mapping, 2018, 39, 3682-3690.	3.6	23
166	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MSâ€MRIUS. Journal of Neuroimaging, 2018, 28, 399-405.	2.0	12
167	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 1703-1709.	2.4	14
168	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. Journal of the Neurological Sciences, 2018, 393, 128-134.	0.6	26
169	Thalamic white matter in multiple sclerosis: A combined diffusionâ€tensor imaging and quantitative susceptibility mapping study. Human Brain Mapping, 2018, 39, 4007-4017.	3.6	19
170	Neck Vessel Crossâ€Sectional Area Measured with MRI: Scanâ€Rescan Reproducibility for Longitudinal Evaluations. Journal of Neuroimaging, 2018, 28, 48-56.	2.0	6
171	Imaging of extracranial obstructive venous disease. Italian Journal of Vascular and Endovascular Surgery, 2018, 25, .	1.0	2
172	Age-related brain atrophy may be mitigated by internal jugular vein enlargement in male individuals without neurologic disease. Phlebology, 2017, 32, 125-134.	1.2	7
173	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. Multiple Sclerosis Journal, 2017, 23, 242-252.	3.0	39
174	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 51-61.	3.0	39
175	White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 107-113.	2.0	25
176	Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlasâ€and voxelâ€based analyses (VBA). Journal of Magnetic Resonance Imaging, 2017, 46, 1474-1484.	3.4	15
177	An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). Magnetic Resonance Imaging, 2017, 39, 110-122.	1.8	36
178	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. Journal of the American College of Cardiology, 2017, 69, 679-691.	2.8	110
179	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. Journal of Neuroimaging, 2017, 27, 620-629.	2.0	20
180	Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2017, 266, 90-95.	1.8	12

#	Article	IF	Citations
181	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practiceâ€"The MSâ€MRIUS Study. Journal of Neuroimaging, 2017, 27, 339-347.	2.0	14
182	Serum lipid profile changes predict neurodegeneration in interferon-Î²1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	4.2	43
183	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 769-779.	2.7	48
184	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 1163-1172.	3.1	28
185	Transcatheter aortic valve replacement: perioperative stroke and beyond. Expert Review of Neurotherapeutics, 2017, 17, 327-334.	2.8	9
186	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 367-377.	2.8	405
187	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Multiple Sclerosis Journal, 2017, 23, 1336-1345.	3.0	93
188	Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsingâ€"remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Multiple Sclerosis Journal, 2017, 23, 818-829.	3.0	31
189	Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1385-1393.	3.0	42
190	Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 792-801.	3.0	38
191	TCT-422 Pre-procedural white matter lesion burden predicts MRI outcomes in transcatheter aortic valve replacement (TAVR): The Sentinel Trial. Journal of the American College of Cardiology, 2017, 70, B173-B174.	2.8	0
192	TCT-425 Impact of cerebral protection in aortic stenosis patients treated with transcatheter aortic valve replacement on functional and structural integrity of the brain: results of a combined patient-level analysis of three randomized controlled trials. Journal of the American College of Cardiology, 2017, 70, B174-B175.	2.8	0
193	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. Current Neurovascular Research, 2017, 14, 266-273.	1.1	7
194	Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis. PLoS ONE, 2017, 12, e0182729.	2.5	12
195	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. Veins and Lymphatics, 2017, 6, .	0.1	2
196	Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. International Journal of MS Care, 2017, 19, 297-302.	1.0	5
197	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	1.9	95
198	Internal Jugular Vein Cross-Sectional Area Enlargement Is Associated with Aging in Healthy Individuals. PLoS ONE, 2016, 11, e0149532.	2.5	20

#	Article	IF	Citations
199	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. European Journal of Neurology, 2016, 23, 1101-1109.	3.3	18
200	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. BMC Neurology, 2016, 16, 108.	1.8	6
201	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	2.8	126
202	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. Expert Review of Neurotherapeutics, 2016, 16, 765-775.	2.8	37
203	Aging and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 717-725.	3.0	128
204	Development Of An Innovative Observational Study To Assess Multiple Sclerosis Disease Progression In Real World Clinical Practice. Value in Health, 2016, 19, A104-A105.	0.3	0
205	Dirtyâ€Appearing White Matter in the Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in Individuals without Neurologic Disease. Journal of Neuroimaging, 2016, 26, 136-143.	2.0	18
206	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.1	42
207	Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. Psychiatry Research - Neuroimaging, 2016, 255, 87-93.	1.8	42
208	Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis. JAMA - Journal of the American Medical Association, 2016, 316, 592.	7.4	284
209	Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2016, 22, 920-927.	1.8	18
210	Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy, 2016, 16, 1151-1162.	3.1	14
211	Role of Neuroimaging in Multiple Sclerosis. , 2016, , 443-478.		0
212	Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurology, 2016, 16, 102.	1.8	11
213	Shedding Risk with Intracerebral Inoculation of Theilerâ€™s Murine Encephalomyelitis Virus. Applied Biosafety, 2016, 21, 142-150.	0.5	1
214	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews Neurology, 2016, 12, 714-722.	10.1	274
215	Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology, 2016, 281, 884-895.	7.3	63
216	Brain atrophy measurements should be used to guide therapy monitoring in MS â€“ YES. Multiple Sclerosis Journal, 2016, 22, 1522-1524.	3.0	12

#	Article	IF	Citations
217	Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 36-42.	3.0	53
218	Thalamus volume and ambulation in multiple sclerosis: a cross-sectional study. Neurodegenerative Disease Management, 2016, 6, 23-29.	2.2	27
219	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e190.	6.0	39
220	Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2016, 57, 64-73.	2.1	22
221	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 937-943.	1.9	15
222	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 1010-1016.	2.4	27
223	The Role of Diagnostic Imaging Techniques for Detection of Extracranial Venous System Abnormalities Associated with Central Nervous System Disorders. , 2016, , 953-979.		0
224	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Multiple Sclerosis Journal, 2016, 22, 1709-1718.	3.0	69
225	Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. Therapeutic Advances in Neurological Disorders, 2016, 9, 105-117.	3.5	4
226	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Multiple Sclerosis Journal, 2016, 22, 1327-1336.	3.0	88
227	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	3.0	37
228	Stable neuropsychiatric status in multiple sclerosis: a 3-year study. Multiple Sclerosis Journal, 2016, 22, 569-574.	3.0	11
229	Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients. PLoS ONE, 2016, 11, e0153960.	2.5	15
230	Olfactory Identification Deficit as a Predictor of White Matter Tract Integrity in Alzheimer's Disease. American Journal of Geriatric Psychiatry, 2015, 23, S103-S104.	1.2	1
231	The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2015, 25, 989-995.	2.0	6
232	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurology, 2015, 15, 232.	1.8	12
233	White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 754-760.	2.0	38
234	Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS. PLoS ONE, 2015, 10, e0123771.	2.5	27

#	Article	IF	Citations
235	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. BMC Neurology, 2015, 15, 135.	1.8	9
236	Immunologic and MRI markers of the therapeutic effect of IFN-Î²-1a in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e176.	6.0	13
237	Quantifying errors in flow measurement using phase contrast magnetic resonance imaging: comparison of several boundary detection methods. Magnetic Resonance Imaging, 2015, 33, 185-193.	1.8	34
238	Effects of diet on brain iron levels among healthy individuals: an MRI pilot study. Neurobiology of Aging, 2015, 36, 1678-1685.	3.1	13
239	Blood circulating microparticle species in relapsingâ€“remitting and secondary progressive multiple sclerosis. A caseâ€“control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. Journal of the Neurological Sciences, 2015, 355, 84-89.	0.6	22
240	Early magnetic resonance imaging predictors of clinical progression after 48Âmonths in clinically isolated syndrome patients treated with intramuscular interferon Î²â€1a. European Journal of Neurology, 2015, 22, 1113-1123.	3.3	25
241	Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense â€œblack holesâ€: a post hoc magnetic resonance imaging analysis. Journal of Neurology, 2015, 262, 648-653.	3.6	19
242	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsingâ€“remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2015, 8, 59-70.	3.5	5
243	Diffusion Tensor Imaging Alterations in Patients With Postconcussion Syndrome Undergoing Exercise Treatment. Journal of Head Trauma Rehabilitation, 2015, 30, E32-E42.	1.7	34
244	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsingâ€“remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. Journal of Neuroimmunology, 2015, 281, 44-50.	2.3	3
245	Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2015, 36, 1874-1883.	2.4	33
246	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	4.2	45
247	Increased contrast enhancing lesion activity in relapsingâ€“remitting multiple sclerosis migraine patients. NeuroImage: Clinical, 2015, 9, 110-116.	2.7	16
248	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. American Journal of Neuroradiology, 2015, 36, 1457-1464.	2.4	13
249	Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Multiple Sclerosis Journal, 2015, 21, 858-865.	3.0	46
250	Iron and Volume in the Deep Gray Matter: Association with Cognitive Impairment in Multiple Sclerosis. American Journal of Neuroradiology, 2015, 36, 57-62.	2.4	32
251	Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS ONE, 2015, 10, e0129503.	2.5	8
252	Time for Change â€“ Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod. European Neurological Review, 2015, 9, 136.	0.5	10

#	Article	IF	Citations
253	Internal jugular vein narrowing and body mass index in healthy individuals and multiple sclerosis patients. Veins and Lymphatics, 2014, 3, .	0.1	9
254	Jugular Venous Reflux and White Matter Abnormalities in Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease, 2014, 39, 601-609.	2.6	67
255	The Role of Diagnostic Imaging Techniques for Detection of Extracranial Venous System Abnormalities Associated with Central Nervous System Disorders. , 2014, , 1-30.		0
256	MRI correlates of disability progression in patients with CIS over 48Âmonths. NeuroImage: Clinical, 2014, 6, 312-319.	2.7	39
257	Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology, 2014, 83, 441-449.	1.1	43
258	Subcortical Atrophy Is Associated with Cognitive Impairment in Mild Parkinson Disease: A Combined Investigation of Volumetric Changes, Cortical Thickness, and Vertex-Based Shape Analysis. American Journal of Neuroradiology, 2014, 35, 2257-2264.	2.4	63
259	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences, 2014, 347, 229-234.	0.6	8
260	Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1109-1115.	1.9	155
261	Characterizing cognitive function during relapse in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1745-1752.	3.0	92
262	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. Human Brain Mapping, 2014, 35, 53-60.	3.6	14
263	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	2.3	21
264	Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature. Clinical Rheumatology, 2014, 33, 1829-1833.	2.2	29
265	Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. European Journal of Neurology, 2014, 21, 1137.	3.3	22
266	No Regional Gray Matter Atrophy Differences between Pediatricâ€•and Adultâ€Onset Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2014, 24, 63-67.	2.0	3
267	Recommendations for Multimodal Noninvasive and Invasive Screening for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency: A Position Statement of the International Society for Neurovascular Disease. Journal of Vascular and Interventional Radiology, 2014, 25, 1785-1794.e17.	0.5	57
268	Phase White Matter Signal Abnormalities in Patients with Clinically Isolated Syndrome and Other Neurologic Disorders. American Journal of Neuroradiology, 2014, 35, 1916-1923.	2.4	11
269	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	2.4	44
270	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	2.5	14

#	Article	IF	Citations
271	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	1.9	35
272	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurology, 2014, 14, 131.	1.8	11
273	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. Journal of Neurology, 2014, 261, 1735-1744.	3.6	45
274	Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2014, 35, 106-112.	2.4	50
275	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. Journal of Magnetic Resonance Imaging, 2014, 40, 1215-1222.	3.4	31
276	Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. NeuroImage, 2014, 90, 207-217.	4.2	48
277	Brain responses to altered auditory feedback during musical keyboard production: An fMRI study. Brain Research, 2014, 1556, 28-37.	2.2	33
278	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.6	20
279	Conventional and Advanced Imaging in Neuromyelitis Optica. American Journal of Neuroradiology, 2014, 35, 1458-1466.	2.4	56
280	Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsingâ€“Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study. PLoS ONE, 2014, 9, e91098.	2.5	17
281	A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. Journal of NeuroVirology, 2013, 19, 351-358.	2.1	138
282	The role of noninvasive and invasive diagnostic imaging techniques for detection of extra-cranial venous system anomalies and developmental variants. BMC Medicine, 2013, 11, 155.	5.5	30
283	Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis. BMC Medicine, 2013, 11, 167.	5.5	5
284	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clinical Neurology and Neurosurgery, 2013, 115, S49-S54.	1.4	2
285	Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. European Journal of Neurology, 2013, 20, 1264-1271.	3.3	19
286	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study. BMC Neurology, 2013, 13, 151.	1.8	15
287	Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. Journal of Neuroinflammation, 2013, 10, 125.	7.2	40
288	Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI. BMC Medical Imaging, 2013, 13, 29.	2.7	4

#	Article	IF	Citations
289	Potential involvement of the extracranial venous system in central nervous system disorders and aging. BMC Medicine, 2013, 11, 260.	5.5	66
290	Is there a link between the extracranial venous system and central nervous system pathology?. BMC Medicine, 2013, 11, 259.	5.5	17
291	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	1.8	4
292	The thalamus and multiple sclerosis. Neurology, 2013, 80, 210-219.	1.1	286
293	Development of gray matter atrophy in relapsingâ€“remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. Clinical Neurology and Neurosurgery, 2013, 115, S42-S48.	1.4	12
294	Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study. Journal of Vascular and Interventional Radiology, 2013, 24, 829-838.	0.5	31
295	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	2.3	14
296	Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. Journal of Vascular and Interventional Radiology, 2013, 24, 1487-1498.e1.	0.5	25
297	Jugular venous reflux and plasma endothelin-1 are associated with cough syncope: a case control pilot study. BMC Neurology, 2013, 13, 9.	1.8	17
298	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	7.3	145
299	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1075-1081.	1.9	36
300	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. American Journal of Neuroradiology, 2013, 34, 1931-1939.	2.4	90
301	Effect of Age on MRI Phase Behavior in the Subcortical Deep Gray Matter of Healthy Individuals. American Journal of Neuroradiology, 2013, 34, 2144-2151.	2.4	29
302	Multimodal imaging in systemic lupus erythematosus patients with diffuse neuropsychiatric involvement. Lupus, 2013, 22, 675-683.	1.6	44
303	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 567-576.	3.0	28
304	Neurosarcoidosis. American Journal of Therapeutics, 2013, 20, 292-299.	0.9	12
305	Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis. Psychosomatic Medicine, 2013, 75, 253-261.	2.0	24
306	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1478-1484.	3.0	85

#	Article	IF	Citations
307	MRI characteristics of familial and sporadic multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1145-1152.	3.0	10
308	Lipid profiles are associated with lesion formation over 24â€…months in interferon-Î² treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	1.9	114
309	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: No. Multiple Sclerosis Journal, 2013, 19, 858-860.	3.0	7
310	Exercise Treatment for Postconcussion Syndrome. Journal of Head Trauma Rehabilitation, 2013, 28, 241-249.	1.7	127
311	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Multiple Sclerosis International, 2013, 2013, 1-8.	0.8	9
312	Three times weekly glatiramer acetate in relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2013, 73, 705-713.	5.3	194
313	Cerebrospinal fluid amyloid-Â and phenotypic heterogeneity in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 537-543.	1.9	56
314	Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 1128-1133.	1.8	22
315	Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimerâ€™s disease. BMC Neurology, 2013, 13, 157.	1.8	31
316	Impact of tissue atrophy on high-pass filtered MRI signal phase-based assessment in large-scale group-comparison studies: a simulation study. Frontiers in Physics, 2013, 1, .	2.1	3
317	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Frontiers in Bioscience - Elite, 2013, E5, 525-532.	1.8	24
318	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	2.5	68
319	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. International Journal of Molecular Sciences, 2012, 13, 5659-5673.	4.1	1
320	Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis versus Healthy Controls. American Journal of Neuroradiology, 2012, 33, 252-258.	2.4	45
321	Unclear Value of Positional MR Angiography in Evaluating Cerebral Venous Outflow Hemodynamics. American Journal of Neuroradiology, 2012, 33, E30-E30.	2.4	1
322	Intra- and Extraluminal Structural and Functional Venous Anomalies in Multiple Sclerosis, as Evidenced by 2 Noninvasive Imaging Techniques. American Journal of Neuroradiology, 2012, 33, 16-23.	2.4	40
323	No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1913-1917.	2.4	15
324	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1573-1578.	2.4	133

#	Article	IF	Citations
325	Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy. American Journal of Neuroradiology, 2012, 33, 1596-1601.	2.4	55
326	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurological Research, 2012, 34, 819-827.	1.3	16
327	Vascular pathology of multiple sclerosis. Neurological Research, 2012, 34, 735-737.	1.3	10
328	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurological Research, 2012, 34, 761-769.	1.3	14
329	Arterial, venous and other vascular risk factors in multiple sclerosis. Neurological Research, 2012, 34, 754-760.	1.3	24
330	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. Neurological Research, 2012, 34, 793-801.	1.3	8
331	Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNÎ²-1a in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1125-1134.	3.0	36
332	Blood Pressure Management and Evolution of Thrombolysis-associated Intracerebral Hemorrhage in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 852-859.	1.6	16
333	Role of Venoplasty for Treatment of Multiple Sclerosis: Value of Open-label Studies and Surrogate Treatment Outcomes. Journal of Vascular and Interventional Radiology, 2012, 23, 1308-1310.	0.5	8
334	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurology, 2012, 12, 26.	1.8	15
335	Brain iron accumulation in aging and neurodegenerative disorders. Expert Review of Neurotherapeutics, 2012, 12, 1467-1480.	2.8	83
336	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. NeuroImage, 2012, 59, 331-339.	4.2	176
337	Improved assessment of multiple sclerosis lesion segmentation agreement via detection and outline error estimates. BMC Medical Imaging, 2012, 12, 17.	2.7	23
338	Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Frontiers in Bioscience - Elite, 2012, E4, 1496-1504.	1.8	10
339	Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Frontiers in Bioscience - Elite, 2012, E4, 1496.	1.8	5
340	Iron deposition in multiple sclerosis lesions measured by susceptibilityâ€weighted imaging filtered phase: A case control study. Journal of Magnetic Resonance Imaging, 2012, 36, 73-83.	3.4	60
341	Cine cerebrospinal fluid imaging in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2012, 36, 825-834.	3.4	46
342	3D FLAIRED: 3D fluid attenuated inversion recovery for enhanced detection of lesions in multiple sclerosis. Magnetic Resonance in Medicine, 2012, 68, 874-881.	3.0	25

#	Article	IF	Citations
343	Patterns of dietary and herbal supplement use by multiple sclerosis patients. Journal of Neurology, 2012, 259, 637-644.	3.6	29
344	Venous Angioplasty in Patients with Multiple Sclerosis: Results of a Pilot Study. European Journal of Vascular and Endovascular Surgery, 2012, 43, 116-122.	1.5	73
345	Regarding CCSVI and MS: A Never-ending Story or a New Chapter?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 129-130.	1.5	3
346	Regarding CCSVI: Is Blinding the Key?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 126.	1.5	0
347	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. Journal of Neuroimmunology, 2012, 243, 61-68.	2.3	27
348	Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis?. BMC Neurology, 2012, 12, 9.	1.8	24
349	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. Journal of Neurology, 2012, 259, 139-146.	3.6	274
350	CMV Infection Attenuates the Disease Course in a Murine Model of Multiple Sclerosis. PLoS ONE, 2012, 7, e32767.	2.5	14
351	Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. Minerva Medica, 2012, 103, 97-102.	0.9	2
352	Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nature Reviews Neurology, 2011, 7, 332-342.	10.1	320
353	Pathophysiology of demyelinating disorders. Pathophysiology, 2011, 18, 1-2.	2.2	5
354	Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. Pathophysiology, 2011, 18, 3-12.	2.2	36
355	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology, 2011, 18, 43-52.	2.2	23
356	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology, 2011, 18, 53-60.	2.2	24
357	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A caseâ€“control diffusion imaging study. Pathophysiology, 2011, 18, 61-68.	2.2	11
358	Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 86-91.	0.6	29
359	Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. PLoS ONE, 2011, 6, e28062.	2.5	40
360	Regionally Distinct White Matter Lesions Do Not Contribute to Regional Gray Matter Atrophy in Patients with Multiple Sclerosis. , 2011, 21, 210-218.		11

#	Article	IF	Citations
361	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	2.3	12
362	Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflammation Research, 2011, 60, 457-465.	4.0	42
363	Iron deposition and inflammation in multiple sclerosis. Which one comes first?. BMC Neuroscience, 2011, 12, 60.	1.9	26
364	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurology, 2011, 11, 128.	1.8	50
365	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Medicine, 2011, 9, 22.	5.5	77
366	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. Journal of Neuroinflammation, 2011, 8, 127.	7.2	186
367	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Movement Disorders, 2011, 26, 297-301.	3.9	50
368	Comment on â€œno evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onsetâ€. Annals of Neurology, 2011, 69, 1062-1063.	5.3	3
369	Use of MR Venography for Characterization of the Extracranial Venous System in Patients with Multiple Sclerosis and Healthy Control Subjects. Radiology, 2011, 258, 562-570.	7.3	81
370	Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. American Journal of Neuroradiology, 2011, 32, 938-946.	2.4	63
371	Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 189-195.	1.9	84
372	Recent Developments in Imaging of Multiple Sclerosis. Neurologist, 2011, 17, 185-204.	0.7	63
373	Chronic cerebrospinal venous insufficiency: Have we found the cause and cure of MS?. Neurology, 2011, 77, 1710-1712.	1.1	2
374	Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Review of Neurotherapeutics, 2011, 11, 1277-1294.	2.8	47
375	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 2011, 77, e124-e126.	1.1	99
376	Information processing speed, neural efficiency, and working memory performance in multiple sclerosis: Differential relationships with structural magnetic resonance imaging. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 1129-1145.	1.3	38
377	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 2011, 77, 138-144.	1.1	189
378	Neuroimaging of Multiple Sclerosis. , 2011, , 81-105.		1

#	Article	IF	Citations
379	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e16802.	2.5	14
380	Advances in Magnetic Resonance Imaging of Multiple Sclerosis. , 2011, , 111-129.		0
381	Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Functional Neurology, 2011, 26, 205-14.	1.3	24
382	Chronic cerebrospinal venous insufficiency in multiple sclerosis: a historical perspective. Functional Neurology, 2011, 26, 181-95.	1.3	15
383	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. Journal of Neurology, 2010, 257, 63-71.	3.6	26
384	Gray matter correlations of cognition in incident Parkinson's disease. Movement Disorders, 2010, 25, 629-633.	3.9	61
385	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28.	3.5	29
386	Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opinion on Biological Therapy, 2010, 10, 421-429.	3.1	29
387	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology, 2010, 74, 538-544.	1.1	58
388	Rapid disease course in African Americans with multiple sclerosis. Neurology, 2010, 75, 217-223.	1.1	106
389	Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist, 2010, 24, 1131-1145.	2.3	205
390	Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis: A Longitudinal, Magnetic Resonance Imaging, Blinded Pilot Study. Journal of Vascular Surgery, 2010, 51, 794.	1.1	1
391	Role of platelets in neuroinflammation: a wide-angle perspective. Journal of Neuroinflammation, 2010, 7, 10.	7.2	86
392	Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS). FASEB Journal, 2010, 24, 332.8.	0.5	0
393	Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. International Angiology, 2010, 29, 127-39.	0.9	66
394	CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. International Angiology, 2010, 29, 140-8.	0.9	24
395	Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. International Angiology, 2010, 29, 158-75.	0.9	54
396	Apolipoprotein E Îµ4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study. Folia Biologica, 2010, 56, 242-51.	0.6	1

#	Article	IF	Citations
397	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 201-206.	1.9	174
398	Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain, 2009, 132, 3392-3400.	7.6	130
399	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 965-976.	3.0	77
400	Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology, 2009, 73, 504-510.	1.1	116
401	Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 620-625.	1.9	58
402	Geneâ€“environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. Journal of Neuroimmunology, 2009, 209, 123-130.	2.3	35
403	Brain atrophy and white matter hyperintensities in early Parkinson's disease. Movement Disorders, 2009, 24, 2233-2241.	3.9	50
404	Retinal architecture predicts pupillary reflex metrics in MS. Multiple Sclerosis Journal, 2009, 15, 479-486.	3.0	20
405	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Multiple Sclerosis Journal, 2009, 15, 345-354.	3.0	62
406	Chapter 4 Neuroimaging of Cognitive Impairments in Vascular Disease. International Review of Neurobiology, 2009, 84, 49-80.	2.0	4
407	Gray matter atrophy and disability progression in patients with early relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 112-119.	0.6	84
408	Extent of cerebellum, subcortical and cortical atrophy in patients with MS. Journal of the Neurological Sciences, 2009, 282, 47-54.	0.6	133
409	Gray matter pathology in (chronic) MS: Modern views on an early observation. Journal of the Neurological Sciences, 2009, 282, 12-20.	0.6	105
410	Evidence for gray matter pathology in multiple sclerosis: A neuroimaging approach. Journal of the Neurological Sciences, 2009, 282, 1-4.	0.6	21
411	A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. Journal of the Neurological Sciences, 2009, 282, 86-95.	0.6	18
412	Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. Journal of the Neurological Sciences, 2009, 282, 96-105.	0.6	110
413	Antiphospholipid antibodies: Paradigm in transition. Journal of Neuroinflammation, 2009, 6, 3.	7.2	37
414	Signal abnormalities on 1.5 and 3ÂTesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. NeuroImage, 2009, 47, 1352-1362.	4.2	26

#	Article	IF	Citations
415	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. NeuroImage, 2009, 47, 2083-2089.	4.2	65
416	Transcranial sonography of deep gray nuclei. Neurology, 2009, 73, 1006-1007.	1.1	0
417	Advanced magnetic resonance imaging metrics: Implications for multiple sclerosis clinical trials. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 29.	0.8	8
418	Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders. , 2009, , 17-54.		0
419	The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Functional Neurology, 2009, 24, 133-8.	1.3	76
420	Advanced magnetic resonance imaging metrics: Implications for multiple sclerosis clinical trials. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 29.	0.8	6
421	Neuropsychological Impairment in Systemic Lupus Erythematosus: A Comparison with Multiple Sclerosis. Neuropsychology Review, 2008, 18, 149-166.	4.9	55
422	The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. Journal of Neurology, 2008, 255, 61-74.	3.6	66
423	Regional Specificity of Magnetization Transfer Imaging in Multiple Sclerosis. Journal of Neuroimaging, 2008, 18, 130-136.	2.0	13
424	Is functional MRI feasible for multiâ€¢center studies on multiple sclerosis?. European Journal of Neurology, 2008, 15, 109-110.	3.3	9
425	Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2008, 267, 28-35.	0.6	28
426	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. Journal of the Neurological Sciences, 2008, 268, 12-17.	0.6	147
427	Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83.	10.9	41
428	Application of hidden Markov random field approach for quantification of perfusion/diffusion mismatch in acute ischemic stroke. Neurological Research, 2008, 30, 827-834.	1.3	13
429	Interferon-Î² treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy, 2008, 8, 1435-1447.	3.1	38
430	Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology, 2008, 71, 136-144.	1.1	227
431	Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity. Multiple Sclerosis Journal, 2008, 14, 759-763.	3.0	43
432	Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. Neurological Research, 2008, 30, 816-826.	1.3	22

#	Article	IF	Citations
433	Modeling Axonal Degeneration Within the Anterior Visual System. Archives of Neurology, 2008, 65, 26-35.	4.5	56
434	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2008, 14, 1061-1067.	3.0	35
435	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	1.9	73
436	Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis. American Journal of Neuroradiology, 2008, 29, 319-325.	2.4	62
437	Cortical atrophy and personality in multiple sclerosis.. Neuropsychology, 2008, 22, 432-441.	1.3	44
438	Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Drugs of Today, 2008, 44, 601.	1.1	3
439	Acute demyelinating optic neuritis: a review. Frontiers in Bioscience - Landmark, 2008, 13, 2376.	3.0	13
440	What you see is what you get: Coupling function with structure in the visual system. Neurology, 2007, 69, 2119-2120.	1.1	1
441	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 475-489.	2.0	25
442	The Role of Quantitative Neuroimaging Indices in the Differentiation of Ischemia From Demyelination: An Analytical Study With Case Presentation. International Review of Neurobiology, 2007, 79, 491-519.	2.0	15
443	Neuroimaging In Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 449-474.	2.0	62
444	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 722-730.	3.0	91
445	Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?. Neurology, 2007, 68, S72-S82.	1.1	87
446	Preservation of gray matter volume in multiple sclerosis patients with the MetÂallele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Human Molecular Genetics, 2007, 16, 2659-2668.	2.9	93
447	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. NeuroImage, 2007, 36, 746-754.	4.2	45
448	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage, 2007, 36, 1294-1300.	4.2	109
449	I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Multiple Sclerosis Journal, 2007, 13, 490-501.	3.0	72
450	Validity of the Wisconsin Card Sorting and Delisâ€“Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 215-223.	1.3	77

#	Article	IF	Citations
451	HLAâ€ÐRB1*1501, â€ÐQB1*0301, â€ÐQB1*0302, â€ÐQB1*0602, and â€ÐQB1*0603 Alleles are Associated With More Severe Disease Outcome on Mri in Patients With Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 521-535.	2.0	60
452	Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations. Neurotherapeutics, 2007, 4, 618-626.	4.4	52
453	Corticosteroids for Multiple Sclerosis: II. Application for Disease-Modifying Effects. Neurotherapeutics, 2007, 4, 627-632.	4.4	5
454	Pharmacogenetics of MXA SNPs in interferon-Î² treated multiple sclerosis patients. Journal of Neuroimmunology, 2007, 182, 236-239.	2.3	38
455	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2007, 187, 159-165.	2.3	43
456	Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 167-174.	2.3	57
457	New MRI criteria in the diagnosis of multiple sclerosis. Lancet Neurology, The, 2007, 6, 664-665.	10.2	6
458	Reliability and validity of neuropsychological screening and assessment strategies in MS. Journal of Neurology, 2007, 254, II22-II25.	3.6	29
459	Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. NeuroImage, 2006, 29, 505-514.	4.2	63
460	Predicting neuropsychological abnormalities in multiple sclerosis. Journal of the Neurological Sciences, 2006, 245, 67-72.	0.6	57
461	Interferon Inhibitory Activity in Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1579.	4.5	17
462	Progressive Cerebral Disease in Lymphomatoid Granulomatosis Causes Anterograde Amnesia and Neuropsychiatric Disorder. Journal of Neuroimaging, 2006, 16, 163-166.	2.0	7
463	A Magnetization Transfer MRI Study of Deep Gray Matter Involvement in Multiple Sclerosis. Journal of Neuroimaging, 2006, 16, 302-310.	2.0	24
464	Optical coherence tomography in multiple sclerosis. Lancet Neurology, The, 2006, 5, 853-863.	10.2	165
465	Dynamics of interferon-Î² modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-Î² neutralizing antibodies. Journal of Neuroimmunology, 2006, 176, 125-133.	2.3	41
466	Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis. Neurological Research, 2006, 28, 275-279.	1.3	8
467	Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurological Research, 2006, 28, 262-269.	1.3	48
468	Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis. Archives of Neurology, 2006, 63, 614.	4.5	81

#	Article	IF	Citations
469	Neocortical Atrophy, Third Ventricular Width, and Cognitive Dysfunction in Multiple Sclerosis. Archives of Neurology, 2006, 63, 1301.	4.5	282
470	Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis. Expert Review of Neurotherapeutics, 2006, 6, 323-331.	2.8	9
471	Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis. , 2005, 15, 10S-21S.		109
472	Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. European Journal of Neurology, 2005, 12, 550-556.	3.3	76
473	Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. Journal of Neuroimaging, 2005, 15, 27-36.	2.0	26
474	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30.	4.5	36
475	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the Neurological Sciences, 2005, 231, 29-34.	0.6	446
476	Title is missing!. Journal of the Neurological Sciences, 2005, 231, 103-104.	0.6	0
477	Steroids and brain atrophy in multiple sclerosis. Journal of the Neurological Sciences, 2005, 233, 73-81.	0.6	39
478	Role of Magnetic Resonance Imaging in the Diagnosis and Prognosis of Multiple Sclerosis. , 2005, , 55-89.		3
479	Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. , 2005, 15, 27-36.		12
480	Regional lobar atrophy predicts memory impairment in multiple sclerosis. American Journal of Neuroradiology, 2005, 26, 1824-31.	2.4	73
481	Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Frontiers in Bioscience - Landmark, 2004, 9, 647.	3.0	70
482	Role of MRI in multiple sclerosis I: inflammation and lesions. Frontiers in Bioscience - Landmark, 2004, 9, 665.	3.0	79
483	Frontal parenchymal atrophy measures in multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 562-568.	3.0	36
484	beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. European Journal of Neurology, 2004, 11, 455-460.	3.3	6
485	Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. Journal of Neuroimaging, 2004, 14, 27S.	2.0	68
486	MMP-9 microsatellite polymorphism and multiple sclerosis. Journal of Neuroimmunology, 2004, 152, 147-153.	2.3	37

#	Article	IF	Citations
487	Short-term brain atrophy changes in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2004, 223, 185-193.	0.6	41
488	Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. NeuroImage, 2004, 22, 1732-1743.	4.2	172
489	Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. , 2004, 14, 27-35.		41
490	Normalized regional brain atrophy measurements in multiple sclerosis. Neuroradiology, 2003, 45, 793-798.	2.2	21
491	HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. Journal of Neurology, 2003, 250, 1099-1106.	3.6	40
492	Risk factors of multiple sclerosis: a case-control study. Neurological Sciences, 2003, 24, 242-247.	1.9	108
493	Migraine and Tension-Type Headache in Croatia: A Population-Based Survey of Precipitating Factors. Cephalalgia, 2003, 23, 336-343.	3.9	127
494	Thalamic Involvement in Multiple Sclerosis: A Diffusionâ€Weighted Magnetic Resonance Imaging Study. Journal of Neuroimaging, 2003, 13, 307-314.	2.0	84
495	Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. Journal of the Neurological Sciences, 2003, 210, 73-76.	0.6	89
496	A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. Journal of the Neurological Sciences, 2003, 216, 113-118.	0.6	73
497	Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 108-110.	3.0	39
498	The Use of Standardized Incidence and Prevalence Rates in Epidemiological Studies on Multiple Sclerosis. Neuroepidemiology, 2003, 22, 65-74.	2.3	94
499	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. , 2003, 13, 307-314.		38
500	Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. , 2003, 13, 307-14.		21
501	Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurologica Scandinavica, 2002, 105, 77-82.	2.1	100
502	Depressive symptoms and MRI changes in multiple sclerosis. European Journal of Neurology, 2002, 9, 491-496.	3.3	72
503	Is Gadolinium Enhancement Predictive of the Development of Brain Atrophy in Multiple Sclerosis? A Review of the Literature. Journal of Neuroimaging, 2002, 12, 302-309.	2.0	25
504	Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. Journal of the Neurological Sciences, 2001, 187, 1-5.	0.6	117

#	Article	IF	Citations
505	Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. Journal of Neurology, 2001, 248, 416-421.	3.6	209
506	Prevalence of Migraine in Croatia: A Population-Based Survey. Headache, 2001, 41, 805-812.	3.9	46
507	MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology, 2001, 43, 272-278.	2.2	109
508	Bilingual Aphasia and Subcortical-Cortical Lesions. Perceptual and Motor Skills, 2001, 92, 803-814.	1.3	43
509	Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology, 2001, 57, 1239-1247.	1.1	338
510	A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 773-780.	1.9	327
511	BILINGUAL APHASIA AND SUBCORTICAL-CORTICAL LESIONS. Perceptual and Motor Skills, 2001, 92, 803.	1.3	4
512	Olfactory dysfunction and extent of white matter abnormalities in multiple sclerosis: a clinical and MR study. Multiple Sclerosis Journal, 2000, 6, 386-390.	3.0	79
513	Olfactory dysfunction and extent of white matter abnormalities in multiple sclerosis: a clinical and MR study. Multiple Sclerosis Journal, 2000, 6, 386-390.	3.0	4
514	Sexual dysfunction in multiple sderosis: a case-control study. 1. Frequency and comparison of groups. Multiple Sclerosis Journal, 1999, 5, 418-427.	3.0	199
515	Olfactory loss in multiple sclerosis. Journal of the Neurological Sciences, 1999, 168, 127-130.	0.6	72
516	Sexual dysfunction in multiple sderosis: II. Correlation analysis. Multiple Sclerosis Journal, 1999, 5, 428-431.	3.0	96
517	Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Multiple Sclerosis Journal, 1999, 5, 418-427.	3.0	125
518	Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Multiple Sclerosis Journal, 1999, 5, 428-431.	3.0	62
519	Incidence and Prevalence of Myasthenia gravis in the County of the Coast and Gorski kotar, Croatia, 1976 through 1996¹. Neuroepidemiology, 1998, 17, 265-272.	2.3	17
520	Incidence and prevalence of motor neuron disease in Coastal and Mountainous Regions, Croatia, 1984â€“1993. A preliminary survey. European Journal of Neurology, 1997, 4, 376-381.	3.3	0
521	Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis. Journal of Neurology, 0, , .	3.6	4